Herpes Marker Testing Market

Herpes Marker Testing Market: Overview

Owing to the high prevalence of herpes simplex virus of both types, HSV- 1 and HSV- 2, the demand for herpes marker testing is receiving a stimulus. According to estimates of Centers for Disease Control and Prevention, each year in the U.S., 776,000 people get new genital herpes infections. Countrywide, 11.9% of the population aged between 14 and 49 years have HSV-2 infection, with African- American female population mainly affected.

Furthermore, according to data presented by the Public Health Agency of Canada, prevalence of HSV-1 infection is higher than HSV-2 in most parts of the world. The data also shows seroprevalence in adults is above 70% in developed countries, and almost 100% in developing and underdeveloped countries.

The study on the herpes marker testing market provides a pinpoint analysis of demand dynamics, growth indices, and vendor landscape of the said market for the 2015 – 2023 forecast period.

Herpes Marker Testing Market: Key Trends

Growth of herpes marker testing market stems from ubiquity of herpes virus and asymptomatic nature of the infection. More than 80% herpes infections are asymptomatic, because of which physicians depend on diagnostic tests for correct diagnosis and treatment. Some symptoms of herpes infection are blistering sores, swollen lymph nodes, pain during urination, and fever.

High risk of contraction of herpes virus by close contact with an infected individual is pushing the growth of herpes marker testing market. The virus is transmitted through body fluids such as blood, saliva, and semen. Some studies suggest herpes virus is transmitted through breast milk.

Less number of diagnostic tests available for herpes simplex virus (HSV) is another factor behind growth of herpes marker testing market. Currently, there are four tests available for HSV biomarker testing, namely, antigen tests, cell culture tests, polymerase chain reaction, and antibody tests. Of all, polymerase chain reaction tests are most accurate for diagnosis of HSV. Whilst, cell culture tests have chance of false negative results, and are time consuming too. This arouses need for new diagnostic tests for HSV biomarker testing.

Herpes Marker Testing Market: Geographical Analysis

North America, among all, is the forefront in terms of clinical trials for herpes marker testing. Medical insurance coverage for HSV testing and presence of state-of-the-art testing facilities are other factors that make the region prominent. High awareness among individuals to seek medical testing for symptomatic HSV also accounts for substantial revenue of the region in the overall herpes marker testing market. Furthermore, higher seroprevalence of HSV and large number of HIV patients are some other factors that pushes growth of North America herpes marker testing market.

On the other hand, limited knowledge of HSV among individuals of developing countries is a factor for small revenue of Asia Pacific herpes marker testing market. Due to the economic conditions and limited medical facilities, cost-effective diagnosis tests are in high demand in developing countries of Asia Pacific.

Herpes Marker Testing Market: Competitive Landscape

Keen players in the herpes marker testing market are making strides for diagnostic tests for HSV1- and HSV- 2. R&D and clinical trials is the focus of top players in the herpes market testing market. In 2014, Simplexa HSV 1 and HSV 2 direct molecular test by Quest Diagnostics are the first ones to receive U.S. FDA’s approval. The Simplexa test is the first one approved by U.S. FDA that enables qualitative differentiation and detection of HSV-1 and HSV- 2 in cerebrospinal fluid.

Some other top players in the herpes marker testing market are Trinity Biotech, Biohelix, Focus Diagnostics, DiaSorin, Roche, Thermo Fisher Scientific, and Enzo Life Sciences.